MHRA Recalls Novartis Cough and Cold Medicine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MHRA Recalls Novartis Cough and Cold Medicine


The Medicines and Healthcare products Regulatory Agency (MHRA) issued a recall on certain batches of Novartis Consumer Health UK Ltd’s Tixylix cough and cold medicines because of a possible fault in the manufacturing process of the tamper seal that might result in small pieces of plastic being found in the liquid medicines. MHRA says that there is no evidence, as of yet, of problems occurring as a result of this manufacturing fault but they are recalling the drugs as a precautionary measure.

“This is a precautionary recall and there is currently no evidence that people have had any problems with these medicines,” said Adam Burgess, the MHRA’s Head of Defective Medicines Reporting Centre (DMRC), in a press release.“If people have bought Tixylix we ask that they check the batch number on the bottle label next to the expiry date to see if it is one of the batches being recalled. If anyone has an affected batch they should return it to the place of purchase for a refund. If people do have any questions they can contact Novartis on 0800 854 100 or visit tixylix.co.uk.”

Specific batches of the Tixylix medicines being recalled by Novartis include:
Tixylix Toddler Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Toddler Syrup 150mL (Glycerol)—PL 00030/0150
Tixylix Baby Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Blackcurrant Flavour Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Chesty Cough 100mL (Guaifenesin)—PL 00030/0082

Source: MHRA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here